These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34826586)

  • 1. Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types.
    Grillo E; Ravelli C; Corsini M; Gaudenzi C; Zammataro L; Mitola S
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166313. PubMed ID: 34826586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.
    Gallo LH; Nelson KN; Meyer AN; Donoghue DJ
    Cytokine Growth Factor Rev; 2015 Aug; 26(4):425-49. PubMed ID: 26003532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains.
    Neilson KM; Friesel R
    J Biol Chem; 1996 Oct; 271(40):25049-57. PubMed ID: 8798788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mutant fibroblast growth factor receptors in cancer.
    Greulich H; Pollock PM
    Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
    Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of ephexin1, a guanine nucleotide exchange factor of Rho family GTPases, by fibroblast growth factor receptor-mediated tyrosine phosphorylation.
    Zhang Y; Sawada T; Jing X; Yokote H; Yan X; Sakaguchi K
    J Biol Chem; 2007 Oct; 282(42):31103-12. PubMed ID: 17702745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors.
    Dai S; Zhou Z; Chen Z; Xu G; Chen Y
    Cells; 2019 Jun; 8(6):. PubMed ID: 31216761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras.
    Galvin BD; Hart KC; Meyer AN; Webster MK; Donoghue DJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7894-9. PubMed ID: 8755573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.
    Serizawa M; Kusuhara M; Ohnami S; Nagashima T; Shimoda Y; Ohshima K; Mochizuki T; Urakami K; Yamaguchi K
    Anticancer Res; 2016 Jun; 36(6):2733-44. PubMed ID: 27272783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of FGFR in oral carcinogenesis.
    Xie X; Wang Z; Chen F; Yuan Y; Wang J; Liu R; Chen Q
    Cell Prolif; 2016 Jun; 49(3):261-9. PubMed ID: 27218663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
    Patani H; Bunney TD; Thiyagarajan N; Norman RA; Ogg D; Breed J; Ashford P; Potterton A; Edwards M; Williams SV; Thomson GS; Pang CS; Knowles MA; Breeze AL; Orengo C; Phillips C; Katan M
    Oncotarget; 2016 Apr; 7(17):24252-68. PubMed ID: 26992226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptors as treatment targets in clinical oncology.
    Katoh M
    Nat Rev Clin Oncol; 2019 Feb; 16(2):105-122. PubMed ID: 30367139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers.
    Wang T; Ruan S; Zhao X; Shi X; Teng H; Zhong J; You M; Xia K; Sun Z; Mao F
    Nucleic Acids Res; 2021 Jan; 49(D1):D1289-D1301. PubMed ID: 33179738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid residues which distinguish the mitogenic potentials of two FGF receptors.
    Wang JK; Goldfarb M
    Oncogene; 1997 Apr; 14(15):1767-78. PubMed ID: 9150382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Resistance Is Oncogene and Drug Agnostic.
    Doebele RC
    Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family.
    Zhang Y; Gorry MC; Post JC; Ehrlich GD
    Gene; 1999 Apr; 230(1):69-79. PubMed ID: 10196476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.